About the Company
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RETA News
Biogen Profit Beats Street Estimates as Cost-Cutting Takes Hold
Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations, as the biotech giant cut costs and its new ...
Reata Pharmaceuticals Stock Plummets More Than 20%: Here's Why
Reata Pharmaceuticals Inc (NASDAQ: RETA) and its partner Kyowa Kirin Co Ltd have decided to discontinue bardoxolone chronic kidney disease programs. In May 2023, Kyowa Kirin announced data from ...
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc. (NASDAQ ...
Reata Pharmaceuticals
Biogen's Reata Pharmaceuticals acquisition brings Skyclarys, the first and only FDA-approved therapy for the rare neuromuscular disease Friedreich’s ataxia. Biogen says Skyclarys complements the ...
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical company focused on ...
Biogen Beats Estimates as Alzheimer’s Drug Gains Traction
Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations as the biotech giant’s new Alzheimer’s drug ...
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals
Projects include: 3401 & 3501 Olympus Blvd, HQ53, Reata Pharmaceuticals, The Offices Two at Frisco Station, and Victory Commons One. North Texas corporate lawyers share insights about moving ...
Loading the latest forecasts...